stockrow
Friday 6 November 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.55
0.16
−9.36%
Follow XTLB
Alert me
XTL Biopharmaceuticals Ltd. (XTLB) P/E ratio
XTL Biopharmaceuticals Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 31.0× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 31.0×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XTLB XTL Biopharmaceuticals Ltd. | n/m |
| MTVA MetaVia Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)